Evaluation of PPP2R5C gene expression in Iranian patients with B-Acute lymphoblastic leukemia and its association with clinical and laboratory findings
E. Rostami, H. Ayatollahi, Hassan Boustani, A. Ghotaslou, M. Sadeghian, M. Keramati, Elahe Zeinali, A. Rad, Cellular Nutrition
{"title":"Evaluation of PPP2R5C gene expression in Iranian patients with B-Acute lymphoblastic leukemia and its association with clinical and laboratory findings","authors":"E. Rostami, H. Ayatollahi, Hassan Boustani, A. Ghotaslou, M. Sadeghian, M. Keramati, Elahe Zeinali, A. Rad, Cellular Nutrition","doi":"10.29252/JBRMS.4.4.8","DOIUrl":null,"url":null,"abstract":"Introduction: PPP2R5C is one of the regulatory B subunits of protein phosphatase 2A (PP2A), which is a tumor suppressor. PPP2R5C plays a critical role in cell proliferation, differentiation, and transformation. Considering these vital functions, we investigate the gene expression in Iranian patients with B-Acute Lymphoblastic Leukemia (B-ALL) and its association with clinical and laboratory finding. Materials and methods: In this case-control study, peripheral blood samples were collected from 60 B-ALL patients and 30 healthy controls. PPP2R5C expression levels were determined by Real-time PCR. After calculation of CT for target and control genes, we calculated ΔCT. Finally we compared the PPP2R5C expression levels in patients with control group. Results: Significantly higher expression of PPP2R5C was found in the B-ALL patients (2.15±2. 50) compared with control group. There was no correlation between PPP2R5C expression and clinical and laboratory findings and FAB (French-American-British) subtype of patients. Conclusion: we demonstrated PPP2R5C overexpression in B-ALL patients. Although there was no significant correlation between PPP2R5C expression, clinical and laboratory finding and also with FAB subtypes of patients.","PeriodicalId":15047,"journal":{"name":"Journal of Basic Research in Medical Sciences","volume":"4 1","pages":"8-12"},"PeriodicalIF":0.0000,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Basic Research in Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29252/JBRMS.4.4.8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: PPP2R5C is one of the regulatory B subunits of protein phosphatase 2A (PP2A), which is a tumor suppressor. PPP2R5C plays a critical role in cell proliferation, differentiation, and transformation. Considering these vital functions, we investigate the gene expression in Iranian patients with B-Acute Lymphoblastic Leukemia (B-ALL) and its association with clinical and laboratory finding. Materials and methods: In this case-control study, peripheral blood samples were collected from 60 B-ALL patients and 30 healthy controls. PPP2R5C expression levels were determined by Real-time PCR. After calculation of CT for target and control genes, we calculated ΔCT. Finally we compared the PPP2R5C expression levels in patients with control group. Results: Significantly higher expression of PPP2R5C was found in the B-ALL patients (2.15±2. 50) compared with control group. There was no correlation between PPP2R5C expression and clinical and laboratory findings and FAB (French-American-British) subtype of patients. Conclusion: we demonstrated PPP2R5C overexpression in B-ALL patients. Although there was no significant correlation between PPP2R5C expression, clinical and laboratory finding and also with FAB subtypes of patients.